Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OP-3136 in Advanced or Metastatic Solid Tumors
NCT06784193Phase 1Recruiting
- Sponsor
- Olema Oncology
- Start
- Dec 2024
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 1, open-label trial of OP-3136 in breast cancer, prostate cancer (PCa) and non-small cell lung cancer (NSCLC) (7 arms), sponsored by Olema Oncology. Primary endpoints: Dose-Limiting Toxicities at 28 days and Adverse Events and Laboratory Abnormalities at 26 months. Started Dec 2024; status: recruiting.
02
Drugs
OP-3136
03
Conditions
breast cancerprostate cancer (PCa)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06784193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06784193.